{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient has a viral load of 150 copies/mL after being undetectable for 2 years. CD4 count is 650. They report missing doses occasionally due to work schedule. What should I consider?", "output": "This represents a low-level viral rebound (viremia) that warrants prompt attention but is not a crisis. Key considerations:\n\n**Immediate Assessment:**\n1. Confirm with repeat viral load testing within 2-4 weeks\n2. Review medication adherence in detail - occasional missed doses can cause blips\n3. Check for drug-drug interactions with any new medications\n4. Assess for recent illness that could affect absorption\n\n**Likely Causes (in order of probability):**\n1. Adherence gaps - most common cause of low-level viremia\n2. Laboratory variation (blip) - single values <200 often resolve\n3. Drug interactions reducing ARV levels\n4. Early resistance development (less likely with good history)\n\n**Recommended Actions:**\n1. Schedule adherence counseling - address work schedule barriers\n2. Consider pill organizers or phone reminders\n3. Repeat viral load in 4 weeks\n4. If persistent >200, consider resistance testing\n5. Maintain current regimen unless resistance confirmed\n\n**Reassurance:** CD4 of 650 indicates preserved immune function. With adherence support, most patients quickly return to undetectable status.", "metadata": {"category": "clinical", "condition": "HIV", "severity": "medium", "evidence_level": "guideline", "clinical_domain": "virology", "source": "synthetic"}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient has a viral load of 150 copies/mL after being undetectable for 2 years. CD4 count is 650. They report missing doses occasionally due to work schedule. What should I consider?", "output": "This represents a low-level viral rebound (viremia) that warrants prompt attention but is not a crisis. Key considerations:\n\n**Immediate Assessment:**\n1. Confirm with repeat viral load testing within 2-4 weeks\n2. Review medication adherence in detail - occasional missed doses can cause blips\n3. Check for drug-drug interactions with any new medications\n4. Assess for recent illness that could affect absorption\n\n**Likely Causes (in order of probability):**\n1. Adherence gaps - most common cause of low-level viremia\n2. Laboratory variation (blip) - single values <200 often resolve\n3. Drug interactions reducing ARV levels\n4. Early resistance development (less likely with good history)\n\n**Recommended Actions:**\n1. Schedule adherence counseling - address work schedule barriers\n2. Consider pill organizers or phone reminders\n3. Repeat viral load in 4 weeks\n4. If persistent >200, consider resistance testing\n5. Maintain current regimen unless resistance confirmed\n\n**Reassurance:** CD4 of 650 indicates preserved immune function. With adherence support, most patients quickly return to undetectable status.", "metadata": {"category": "clinical", "condition": "HIV", "severity": "medium", "evidence_level": "guideline", "clinical_domain": "virology", "source": "synthetic_balanced", "gender_balanced": true}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Newly diagnosed HIV patient, CD4 count 180, viral load 250,000. No prior treatment. They're anxious about starting medications. What's the approach?", "output": "This patient has advanced HIV infection requiring urgent but compassionate initiation of antiretroviral therapy (ART).\n\n**Clinical Urgency:**\n- CD4 <200 = AIDS-defining immunosuppression\n- High viral load increases transmission risk and disease progression\n- Opportunistic infection risk is elevated\n\n**Recommended Immediate Steps:**\n1. **OI Prophylaxis:** Start TMP-SMX for PCP prophylaxis (CD4 <200)\n2. **Baseline Testing:** Resistance genotype, HLA-B*5701, hepatitis panel, renal/liver function, lipids\n3. **OI Screening:** TB testing, toxoplasma IgG, CMV IgG\n\n**ART Initiation (same-day or rapid start preferred):**\n- Consider bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) as first-line\n- Single tablet regimen improves adherence\n- Can start before genotype results in most cases\n\n**Addressing Anxiety:**\n1. Normalize their feelings - anxiety at diagnosis is universal\n2. Emphasize: HIV is now a manageable chronic condition\n3. Share that most patients achieve undetectable status within 3-6 months\n4. Connect with peer support or patient navigator\n5. Discuss U=U (Undetectable = Untransmittable) as motivation\n6. Schedule frequent early follow-ups for support\n\n**Expected Outcomes:**\n- 1-2 log viral load drop in first month\n- Undetectable (<50) typically by 3-6 months\n- CD4 recovery of 50-100 cells/year expected", "metadata": {"category": "clinical", "condition": "HIV", "severity": "high", "evidence_level": "guideline", "clinical_domain": "treatment_initiation", "source": "synthetic"}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Newly diagnosed HIV patient, CD4 count 180, viral load 250,000. No prior treatment. They're anxious about starting medications. What's the approach?", "output": "This patient has advanced HIV infection requiring urgent but compassionate initiation of antiretroviral therapy (ART).\n\n**Clinical Urgency:**\n- CD4 <200 = AIDS-defining immunosuppression\n- High viral load increases transmission risk and disease progression\n- Opportunistic infection risk is elevated\n\n**Recommended Immediate Steps:**\n1. **OI Prophylaxis:** Start TMP-SMX for PCP prophylaxis (CD4 <200)\n2. **Baseline Testing:** Resistance genotype, HLA-B*5701, hepatitis panel, renal/liver function, lipids\n3. **OI Screening:** TB testing, toxoplasma IgG, CMV IgG\n\n**ART Initiation (same-day or rapid start preferred):**\n- Consider bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) as first-line\n- Single tablet regimen improves adherence\n- Can start before genotype results in most cases\n\n**Addressing Anxiety:**\n1. Normalize their feelings - anxiety at diagnosis is universal\n2. Emphasize: HIV is now a manageable chronic condition\n3. Share that most patients achieve undetectable status within 3-6 months\n4. Connect with peer support or patient navigator\n5. Discuss U=U (Undetectable = Untransmittable) as motivation\n6. Schedule frequent early follow-ups for support\n\n**Expected Outcomes:**\n- 1-2 log viral load drop in first month\n- Undetectable (<50) typically by 3-6 months\n- CD4 recovery of 50-100 cells/year expected", "metadata": {"category": "clinical", "condition": "HIV", "severity": "high", "evidence_level": "guideline", "clinical_domain": "treatment_initiation", "source": "synthetic_balanced", "gender_balanced": true}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient on Biktarvy for 3 years, consistently undetectable. Now diagnosed with active TB. How should we manage their HIV treatment?", "output": "HIV-TB co-treatment requires careful management due to significant drug interactions. This is a complex but manageable situation.\n\n**Critical Drug Interaction:**\nRifampin (standard TB treatment) is a potent CYP3A4 and UGT1A1 inducer that significantly reduces bictegravir levels, making Biktarvy contraindicated during rifampin-based TB treatment.\n\n**Recommended ARV Switch Options:**\n\n**Option 1 (Preferred):** Dolutegravir 50mg TWICE daily + TDF/FTC or TAF/FTC\n- DTG dose doubled to overcome rifampin induction\n- Well-studied, effective, and well-tolerated\n\n**Option 2:** Efavirenz-based regimen (if no prior NNRTI resistance)\n- EFV 600mg + TDF/FTC\n- Standard dosing with rifampin\n\n**TB Treatment Regimen:**\n- Standard 4-drug induction: Rifampin, Isoniazid, Pyrazinamide, Ethambutol\n- Continue rifampin throughout (6+ months)\n- Add pyridoxine (B6) to prevent INH neuropathy\n\n**Timing Considerations:**\n- Can start TB treatment immediately\n- If new to ART, consider 2-8 week delay to reduce IRIS risk\n- Since patient is already virally suppressed, switch ARV and continue\n\n**Monitoring:**\n- LFTs monthly (hepatotoxicity risk)\n- Viral load at 4 weeks post-switch, then quarterly\n- Watch for IRIS symptoms (paradoxical worsening)\n\n**After TB Treatment Complete:**\nCan switch back to Biktarvy 2 weeks after rifampin discontinued.", "metadata": {"category": "clinical", "condition": "HIV_TB_coinfection", "severity": "high", "evidence_level": "guideline", "clinical_domain": "drug_interactions", "source": "synthetic"}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient on Biktarvy for 3 years, consistently undetectable. Now diagnosed with active TB. How should we manage their HIV treatment?", "output": "HIV-TB co-treatment requires careful management due to significant drug interactions. This is a complex but manageable situation.\n\n**Critical Drug Interaction:**\nRifampin (standard TB treatment) is a potent CYP3A4 and UGT1A1 inducer that significantly reduces bictegravir levels, making Biktarvy contraindicated during rifampin-based TB treatment.\n\n**Recommended ARV Switch Options:**\n\n**Option 1 (Preferred):** Dolutegravir 50mg TWICE daily + TDF/FTC or TAF/FTC\n- DTG dose doubled to overcome rifampin induction\n- Well-studied, effective, and well-tolerated\n\n**Option 2:** Efavirenz-based regimen (if no prior NNRTI resistance)\n- EFV 600mg + TDF/FTC\n- Standard dosing with rifampin\n\n**TB Treatment Regimen:**\n- Standard 4-drug induction: Rifampin, Isoniazid, Pyrazinamide, Ethambutol\n- Continue rifampin throughout (6+ months)\n- Add pyridoxine (B6) to prevent INH neuropathy\n\n**Timing Considerations:**\n- Can start TB treatment immediately\n- If new to ART, consider 2-8 week delay to reduce IRIS risk\n- Since patient is already virally suppressed, switch ARV and continue\n\n**Monitoring:**\n- LFTs monthly (hepatotoxicity risk)\n- Viral load at 4 weeks post-switch, then quarterly\n- Watch for IRIS symptoms (paradoxical worsening)\n\n**After TB Treatment Complete:**\nCan switch back to Biktarvy 2 weeks after rifampin discontinued.", "metadata": {"category": "clinical", "condition": "HIV_TB_coinfection", "severity": "high", "evidence_level": "guideline", "clinical_domain": "drug_interactions", "source": "synthetic_balanced", "gender_balanced": true}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Pregnant patient, newly diagnosed HIV, 14 weeks gestation. Viral load 45,000, CD4 380. What are the treatment priorities?", "output": "Pregnancy with newly diagnosed HIV requires immediate action to protect both mother and baby. This is time-sensitive but manageable.\n\n**Primary Goals:**\n1. Achieve viral suppression before delivery (prevents mother-to-child transmission)\n2. Maintain maternal health\n3. Minimize fetal exposure to both virus and unnecessary medications\n\n**Immediate Actions:**\n\n**ART Initiation (Start Immediately):**\n- **Preferred:** Dolutegravir + TAF/FTC (Descovy) or TDF/FTC\n  - DTG now approved for all trimesters (neural tube risk resolved with data)\n  - Rapid viral load decline crucial before delivery\n- **Alternative:** Raltegravir + TDF/FTC if DTG unavailable\n\n**Key Points for 14-Week Gestation:**\n- Past first trimester, many concerns reduced\n- ~26 weeks until delivery - adequate time for viral suppression\n- Target: Undetectable by 36 weeks minimum\n\n**Monitoring Schedule:**\n- Viral load: 2-4 weeks after starting, then monthly until undetectable\n- CD4: Each trimester\n- Standard prenatal care plus HIV-specific monitoring\n\n**Delivery Planning:**\n- If VL <50 near delivery: Vaginal delivery appropriate\n- If VL >1000 near delivery: Scheduled C-section at 38 weeks\n- If VL 50-999: Individualized decision\n\n**Infant Prophylaxis (plan now):**\n- Low risk (mom undetectable): Zidovudine 4 weeks\n- High risk (mom detectable): Triple ARV prophylaxis\n\n**Support Needs:**\n- Prenatal care coordination\n- Adherence support (pregnancy symptoms can affect adherence)\n- Emotional support for dual diagnosis\n- Infant feeding counseling (formula recommended in US)\n\n**Prognosis:** With immediate treatment, MTCT risk <1%.", "metadata": {"category": "clinical", "condition": "HIV_pregnancy", "severity": "high", "evidence_level": "guideline", "clinical_domain": "perinatal", "source": "synthetic"}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Pregnant patient, newly diagnosed HIV, 14 weeks gestation. Viral load 45,000, CD4 380. What are the treatment priorities?", "output": "Pregnancy with newly diagnosed HIV requires immediate action to protect both mother and baby. This is time-sensitive but manageable.\n\n**Primary Goals:**\n1. Achieve viral suppression before delivery (prevents mother-to-child transmission)\n2. Maintain maternal health\n3. Minimize fetal exposure to both virus and unnecessary medications\n\n**Immediate Actions:**\n\n**ART Initiation (Start Immediately):**\n- **Preferred:** Dolutegravir + TAF/FTC (Descovy) or TDF/FTC\n  - DTG now approved for all trimesters (neural tube risk resolved with data)\n  - Rapid viral load decline crucial before delivery\n- **Alternative:** Raltegravir + TDF/FTC if DTG unavailable\n\n**Key Points for 14-Week Gestation:**\n- Past first trimester, many concerns reduced\n- ~26 weeks until delivery - adequate time for viral suppression\n- Target: Undetectable by 36 weeks minimum\n\n**Monitoring Schedule:**\n- Viral load: 2-4 weeks after starting, then monthly until undetectable\n- CD4: Each trimester\n- Standard prenatal care plus HIV-specific monitoring\n\n**Delivery Planning:**\n- If VL <50 near delivery: Vaginal delivery appropriate\n- If VL >1000 near delivery: Scheduled C-section at 38 weeks\n- If VL 50-999: Individualized decision\n\n**Infant Prophylaxis (plan now):**\n- Low risk (mom undetectable): Zidovudine 4 weeks\n- High risk (mom detectable): Triple ARV prophylaxis\n\n**Support Needs:**\n- Prenatal care coordination\n- Adherence support (pregnancy symptoms can affect adherence)\n- Emotional support for dual diagnosis\n- Infant feeding counseling (formula recommended in US)\n\n**Prognosis:** With immediate treatment, MTCT risk <1%.", "metadata": {"category": "clinical", "condition": "HIV_pregnancy", "severity": "high", "evidence_level": "guideline", "clinical_domain": "perinatal", "source": "synthetic_balanced", "gender_balanced": true}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Long-term survivor, 62 years old, HIV+ for 30 years, currently on Triumeq. Labs show eGFR 48, mild proteinuria. They also have hypertension and early osteopenia. Should we change anything?", "output": "This patient represents the growing population of aging people with HIV who require careful management of both HIV and age-related comorbidities. Several issues need attention.\n\n**Renal Concerns (eGFR 48, proteinuria):**\n\n**Assessment:**\n- eGFR 48 = Stage 3a CKD - moderate concern\n- Triumeq contains abacavir (not nephrotoxic) but check full med list\n- Proteinuria suggests glomerular involvement\n\n**Recommendations:**\n1. Nephrology referral for CKD staging and cause evaluation\n2. Rule out HIV-associated nephropathy (HIVAN) - though rare when suppressed\n3. Optimize BP control (target <130/80 for CKD)\n4. Consider ACE-I or ARB for proteinuria\n5. Avoid NSAIDs, contrast dye when possible\n\n**ARV Considerations:**\n- Triumeq (ABC/DTG/3TC) is renally safe - no change needed for kidneys\n- Avoid TDF-containing regimens\n- TAF acceptable but monitor\n\n**Bone Health (Osteopenia):**\n\n**Risk Factors Present:**\n- Age 62, long HIV duration, likely prior TDF exposure\n- HIV itself increases bone turnover\n\n**Recommendations:**\n1. DEXA scan if not recent\n2. Vitamin D level and supplementation (target >30)\n3. Calcium 1200mg daily\n4. Weight-bearing exercise\n5. Fall prevention assessment\n6. Consider bisphosphonate if T-score <-2.5 or fragility fracture\n\n**Hypertension:**\n- Target <130/80 given CKD and cardiovascular risk\n- First-line: ACE-I or ARB (dual benefit for proteinuria)\n- Lifestyle: sodium restriction, DASH diet\n\n**Polypharmacy Review:**\n- At 62 with multiple conditions, review all medications for interactions\n- Common issues: statins, antihypertensives, PPIs\n\n**Screening Reminder (Aging with HIV):**\n- Annual: lipids, glucose/HbA1c, colonoscopy per guidelines\n- Cardiovascular risk assessment (consider coronary calcium scoring)\n\n**No ARV change needed currently** - Triumeq is a good choice for this profile.", "metadata": {"category": "clinical", "condition": "HIV_aging", "severity": "medium", "evidence_level": "guideline", "clinical_domain": "comorbidity_management", "source": "synthetic"}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Long-term survivor, 62 years old, HIV+ for 30 years, currently on Triumeq. Labs show eGFR 48, mild proteinuria. They also have hypertension and early osteopenia. Should we change anything?", "output": "This patient represents the growing population of aging people with HIV who require careful management of both HIV and age-related comorbidities. Several issues need attention.\n\n**Renal Concerns (eGFR 48, proteinuria):**\n\n**Assessment:**\n- eGFR 48 = Stage 3a CKD - moderate concern\n- Triumeq contains abacavir (not nephrotoxic) but check full med list\n- Proteinuria suggests glomerular involvement\n\n**Recommendations:**\n1. Nephrology referral for CKD staging and cause evaluation\n2. Rule out HIV-associated nephropathy (HIVAN) - though rare when suppressed\n3. Optimize BP control (target <130/80 for CKD)\n4. Consider ACE-I or ARB for proteinuria\n5. Avoid NSAIDs, contrast dye when possible\n\n**ARV Considerations:**\n- Triumeq (ABC/DTG/3TC) is renally safe - no change needed for kidneys\n- Avoid TDF-containing regimens\n- TAF acceptable but monitor\n\n**Bone Health (Osteopenia):**\n\n**Risk Factors Present:**\n- Age 62, long HIV duration, likely prior TDF exposure\n- HIV itself increases bone turnover\n\n**Recommendations:**\n1. DEXA scan if not recent\n2. Vitamin D level and supplementation (target >30)\n3. Calcium 1200mg daily\n4. Weight-bearing exercise\n5. Fall prevention assessment\n6. Consider bisphosphonate if T-score <-2.5 or fragility fracture\n\n**Hypertension:**\n- Target <130/80 given CKD and cardiovascular risk\n- First-line: ACE-I or ARB (dual benefit for proteinuria)\n- Lifestyle: sodium restriction, DASH diet\n\n**Polypharmacy Review:**\n- At 62 with multiple conditions, review all medications for interactions\n- Common issues: statins, antihypertensives, PPIs\n\n**Screening Reminder (Aging with HIV):**\n- Annual: lipids, glucose/HbA1c, colonoscopy per guidelines\n- Cardiovascular risk assessment (consider coronary calcium scoring)\n\n**No ARV change needed currently** - Triumeq is a good choice for this profile.", "metadata": {"category": "clinical", "condition": "HIV_aging", "severity": "medium", "evidence_level": "guideline", "clinical_domain": "comorbidity_management", "source": "synthetic_balanced", "gender_balanced": true}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient with HIV wants to understand what their lab results mean. CD4 count went from 450 to 520, CD4% is 28%, viral load is <20 (undetectable). Is this good?", "output": "These results are excellent! Let me explain what each number means in plain terms.\n\n**Viral Load: <20 copies/mL (Undetectable)**\n\nThis is the most important number. It means:\n- Your HIV medication is working perfectly\n- The virus is suppressed to levels too low to measure\n- Your immune system can recover without viral interference\n- You cannot transmit HIV to sexual partners (U=U: Undetectable = Untransmittable)\n- This is the goal of treatment, and you've achieved it!\n\n**CD4 Count: 450 → 520 cells/μL**\n\nThis is great progress! Here's what it means:\n- CD4 cells are the immune cells HIV attacks\n- Normal range is 500-1500\n- Your count increased by 70 cells - your immune system is rebuilding\n- Above 500 = near-normal immune function\n- Above 200 = low risk for most opportunistic infections\n\n**CD4 Percentage: 28%**\n\nThis is a healthy percentage:\n- Normal is typically >25%\n- CD4% is more stable than absolute count (less variation day-to-day)\n- 28% confirms your immune system is in good shape\n\n**What This Means for Your Health:**\n\n1. **Your treatment is successful** - Keep taking medications as prescribed\n2. **Your immune system is strong** - You can fight off normal infections\n3. **Your life expectancy** - With continued treatment, approaches that of HIV-negative individuals\n4. **Your risk to partners** - Zero when undetectable (U=U is scientifically proven)\n\n**Keep Up the Great Work:**\n- Continue taking your medications daily\n- Attend regular check-ups (typically every 3-6 months when stable)\n- Your next viral load check will confirm continued suppression\n\nYou should feel proud of managing your health so well!", "metadata": {"category": "clinical", "condition": "HIV", "severity": "low", "evidence_level": "guideline", "clinical_domain": "patient_education", "source": "synthetic"}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient with HIV wants to understand what their lab results mean. CD4 count went from 450 to 520, CD4% is 28%, viral load is <20 (undetectable). Is this good?", "output": "These results are excellent! Let me explain what each number means in plain terms.\n\n**Viral Load: <20 copies/mL (Undetectable)**\n\nThis is the most important number. It means:\n- Your HIV medication is working perfectly\n- The virus is suppressed to levels too low to measure\n- Your immune system can recover without viral interference\n- You cannot transmit HIV to sexual partners (U=U: Undetectable = Untransmittable)\n- This is the goal of treatment, and you've achieved it!\n\n**CD4 Count: 450 → 520 cells/μL**\n\nThis is great progress! Here's what it means:\n- CD4 cells are the immune cells HIV attacks\n- Normal range is 500-1500\n- Your count increased by 70 cells - your immune system is rebuilding\n- Above 500 = near-normal immune function\n- Above 200 = low risk for most opportunistic infections\n\n**CD4 Percentage: 28%**\n\nThis is a healthy percentage:\n- Normal is typically >25%\n- CD4% is more stable than absolute count (less variation day-to-day)\n- 28% confirms your immune system is in good shape\n\n**What This Means for Your Health:**\n\n1. **Your treatment is successful** - Keep taking medications as prescribed\n2. **Your immune system is strong** - You can fight off normal infections\n3. **Your life expectancy** - With continued treatment, approaches that of HIV-negative individuals\n4. **Your risk to partners** - Zero when undetectable (U=U is scientifically proven)\n\n**Keep Up the Great Work:**\n- Continue taking your medications daily\n- Attend regular check-ups (typically every 3-6 months when stable)\n- Your next viral load check will confirm continued suppression\n\nYou should feel proud of managing your health so well!", "metadata": {"category": "clinical", "condition": "HIV", "severity": "low", "evidence_level": "guideline", "clinical_domain": "patient_education", "source": "synthetic_balanced", "gender_balanced": true}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient reports severe rash 10 days after starting abacavir. They also have fever, fatigue, and mild nausea. What should we do?", "output": "**URGENT: This presentation is highly concerning for Abacavir Hypersensitivity Reaction (ABC HSR). Immediate action required.**\n\n**Clinical Assessment:**\n\nThe symptom constellation is classic for ABC HSR:\n- Rash (present in ~70% of cases)\n- Fever (present in ~80%)\n- Fatigue/malaise\n- GI symptoms (nausea)\n- Onset within 6 weeks (typically days 9-11, exactly this timing)\n\n**IMMEDIATE ACTIONS:**\n\n1. **STOP ABACAVIR IMMEDIATELY** - Do not wait for confirmation\n2. **Do NOT rechallenge** - Rechallenge can cause fatal anaphylaxis\n3. **Document allergy** - Add permanent alert in medical record\n4. **Symptom management:**\n   - Antihistamines for rash\n   - Antipyretics for fever\n   - Supportive care\n\n**Clinical Course After Stopping:**\n- Symptoms typically resolve within 48-72 hours\n- If symptoms worsen after stopping, consider alternative diagnoses\n- Complete resolution expected within 1 week\n\n**Alternative ARV Regimen:**\n\nReplace Triumeq (ABC/DTG/3TC) with:\n- **Option 1:** Biktarvy (BIC/TAF/FTC) - single tablet, once daily\n- **Option 2:** Dolutegravir + TAF/FTC (Descovy)\n- **Option 3:** Dolutegravir + TDF/FTC (generic available)\n\nStart alternative regimen within 1-2 days to avoid treatment interruption.\n\n**HLA-B*5701 Testing:**\n- Should have been done before starting abacavir\n- If not done, test now for documentation\n- Positive test confirms genetic susceptibility\n- Negative test does NOT rule out HSR (clinical diagnosis)\n\n**Patient Education:**\n- ABC HSR is a known, predictable reaction\n- They must NEVER take abacavir again\n- Carry allergy card\n- Inform all healthcare providers\n\n**Follow-up:**\n- Phone check in 24-48 hours\n- Office visit in 1 week\n- Viral load in 4 weeks on new regimen\n\n**Prognosis:** Excellent with prompt discontinuation and alternative therapy.", "metadata": {"category": "clinical", "condition": "HIV_drug_reaction", "severity": "critical", "evidence_level": "guideline", "clinical_domain": "adverse_events", "source": "synthetic"}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient reports severe rash 10 days after starting abacavir. They also have fever, fatigue, and mild nausea. What should we do?", "output": "**URGENT: This presentation is highly concerning for Abacavir Hypersensitivity Reaction (ABC HSR). Immediate action required.**\n\n**Clinical Assessment:**\n\nThe symptom constellation is classic for ABC HSR:\n- Rash (present in ~70% of cases)\n- Fever (present in ~80%)\n- Fatigue/malaise\n- GI symptoms (nausea)\n- Onset within 6 weeks (typically days 9-11, exactly this timing)\n\n**IMMEDIATE ACTIONS:**\n\n1. **STOP ABACAVIR IMMEDIATELY** - Do not wait for confirmation\n2. **Do NOT rechallenge** - Rechallenge can cause fatal anaphylaxis\n3. **Document allergy** - Add permanent alert in medical record\n4. **Symptom management:**\n   - Antihistamines for rash\n   - Antipyretics for fever\n   - Supportive care\n\n**Clinical Course After Stopping:**\n- Symptoms typically resolve within 48-72 hours\n- If symptoms worsen after stopping, consider alternative diagnoses\n- Complete resolution expected within 1 week\n\n**Alternative ARV Regimen:**\n\nReplace Triumeq (ABC/DTG/3TC) with:\n- **Option 1:** Biktarvy (BIC/TAF/FTC) - single tablet, once daily\n- **Option 2:** Dolutegravir + TAF/FTC (Descovy)\n- **Option 3:** Dolutegravir + TDF/FTC (generic available)\n\nStart alternative regimen within 1-2 days to avoid treatment interruption.\n\n**HLA-B*5701 Testing:**\n- Should have been done before starting abacavir\n- If not done, test now for documentation\n- Positive test confirms genetic susceptibility\n- Negative test does NOT rule out HSR (clinical diagnosis)\n\n**Patient Education:**\n- ABC HSR is a known, predictable reaction\n- They must NEVER take abacavir again\n- Carry allergy card\n- Inform all healthcare providers\n\n**Follow-up:**\n- Phone check in 24-48 hours\n- Office visit in 1 week\n- Viral load in 4 weeks on new regimen\n\n**Prognosis:** Excellent with prompt discontinuation and alternative therapy.", "metadata": {"category": "clinical", "condition": "HIV_drug_reaction", "severity": "critical", "evidence_level": "guideline", "clinical_domain": "adverse_events", "source": "synthetic_balanced", "gender_balanced": true}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient with HIV and hepatitis C coinfection. Genotype 1a, no cirrhosis, treatment-naive for HCV. HIV well controlled on Biktarvy. What are the HCV treatment options?", "output": "Excellent scenario for HCV cure! HIV/HCV coinfection management has become straightforward with modern direct-acting antivirals (DAAs).\n\n**Current Status Assessment:**\n- HIV: Well controlled on Biktarvy (BIC/TAF/FTC) - excellent\n- HCV: Genotype 1a, no cirrhosis, treatment-naive - favorable profile\n- Cure rates for this profile: >95%\n\n**HCV Treatment Options:**\n\n**Preferred Regimens (AASLD/IDSA Guidelines):**\n\n**1. Glecaprevir/Pibrentasvir (Mavyret)**\n- Dose: 3 tablets once daily with food\n- Duration: 8 weeks (treatment-naive, no cirrhosis)\n- Pros: Shortest duration, pangenotypic\n- Drug interactions with Biktarvy: NONE - safe combination\n\n**2. Sofosbuvir/Velpatasvir (Epclusa)**\n- Dose: 1 tablet once daily\n- Duration: 12 weeks\n- Pros: Once daily single tablet, pangenotypic\n- Drug interactions with Biktarvy: NONE - safe combination\n\n**3. Sofosbuvir/Ledipasvir (Harvoni)**\n- Dose: 1 tablet once daily\n- Duration: 8-12 weeks\n- Note: Genotype 1 specific (not pangenotypic)\n- Drug interactions with Biktarvy: Monitor renal function (TAF/SOF)\n\n**Recommendation: Mavyret (8 weeks)**\n- Shortest treatment duration\n- No drug interactions with Biktarvy\n- Once daily with food\n- High efficacy (>97% SVR12)\n\n**Pre-Treatment Workup:**\n1. Confirm no cirrhosis (FIB-4 score, consider FibroScan)\n2. HCV viral load (baseline)\n3. Hepatic function panel\n4. CBC\n5. HBV status (sAg, cAb, sAb) - risk of HBV reactivation\n\n**Monitoring During Treatment:**\n- Week 4: HCV viral load (optional, for adherence assessment)\n- End of treatment: HCV viral load\n- SVR12: HCV viral load 12 weeks post-treatment (defines cure)\n\n**HIV Monitoring:**\n- Continue Biktarvy unchanged\n- HIV viral load per usual schedule\n- No ARV changes needed\n\n**Expected Outcome:**\n- SVR12 (cure) rate: 97-99%\n- Liver inflammation will resolve\n- Fibrosis may regress over time\n- Reduced liver-related mortality\n\n**Post-Cure:**\n- HCV antibody will remain positive (this is normal)\n- Annual HCV RNA if ongoing risk behaviors\n- Reduced hepatocellular carcinoma risk (but not zero - continue surveillance if advanced fibrosis)", "metadata": {"category": "clinical", "condition": "HIV_HCV_coinfection", "severity": "medium", "evidence_level": "guideline", "clinical_domain": "coinfection_management", "source": "synthetic"}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient with HIV and hepatitis C coinfection. Genotype 1a, no cirrhosis, treatment-naive for HCV. HIV well controlled on Biktarvy. What are the HCV treatment options?", "output": "Excellent scenario for HCV cure! HIV/HCV coinfection management has become straightforward with modern direct-acting antivirals (DAAs).\n\n**Current Status Assessment:**\n- HIV: Well controlled on Biktarvy (BIC/TAF/FTC) - excellent\n- HCV: Genotype 1a, no cirrhosis, treatment-naive - favorable profile\n- Cure rates for this profile: >95%\n\n**HCV Treatment Options:**\n\n**Preferred Regimens (AASLD/IDSA Guidelines):**\n\n**1. Glecaprevir/Pibrentasvir (Mavyret)**\n- Dose: 3 tablets once daily with food\n- Duration: 8 weeks (treatment-naive, no cirrhosis)\n- Pros: Shortest duration, pangenotypic\n- Drug interactions with Biktarvy: NONE - safe combination\n\n**2. Sofosbuvir/Velpatasvir (Epclusa)**\n- Dose: 1 tablet once daily\n- Duration: 12 weeks\n- Pros: Once daily single tablet, pangenotypic\n- Drug interactions with Biktarvy: NONE - safe combination\n\n**3. Sofosbuvir/Ledipasvir (Harvoni)**\n- Dose: 1 tablet once daily\n- Duration: 8-12 weeks\n- Note: Genotype 1 specific (not pangenotypic)\n- Drug interactions with Biktarvy: Monitor renal function (TAF/SOF)\n\n**Recommendation: Mavyret (8 weeks)**\n- Shortest treatment duration\n- No drug interactions with Biktarvy\n- Once daily with food\n- High efficacy (>97% SVR12)\n\n**Pre-Treatment Workup:**\n1. Confirm no cirrhosis (FIB-4 score, consider FibroScan)\n2. HCV viral load (baseline)\n3. Hepatic function panel\n4. CBC\n5. HBV status (sAg, cAb, sAb) - risk of HBV reactivation\n\n**Monitoring During Treatment:**\n- Week 4: HCV viral load (optional, for adherence assessment)\n- End of treatment: HCV viral load\n- SVR12: HCV viral load 12 weeks post-treatment (defines cure)\n\n**HIV Monitoring:**\n- Continue Biktarvy unchanged\n- HIV viral load per usual schedule\n- No ARV changes needed\n\n**Expected Outcome:**\n- SVR12 (cure) rate: 97-99%\n- Liver inflammation will resolve\n- Fibrosis may regress over time\n- Reduced liver-related mortality\n\n**Post-Cure:**\n- HCV antibody will remain positive (this is normal)\n- Annual HCV RNA if ongoing risk behaviors\n- Reduced hepatocellular carcinoma risk (but not zero - continue surveillance if advanced fibrosis)", "metadata": {"category": "clinical", "condition": "HIV_HCV_coinfection", "severity": "medium", "evidence_level": "guideline", "clinical_domain": "coinfection_management", "source": "synthetic_balanced", "gender_balanced": true}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient asking about PrEP for their HIV-negative partner. The patient has been undetectable for 5 years. Is PrEP still recommended?", "output": "This is a great question that reflects how well-informed your patients are about HIV prevention! Let me provide a comprehensive answer.\n\n**The Science: U=U (Undetectable = Untransmittable)**\n\nThree landmark studies definitively proved that people with sustained undetectable viral loads cannot transmit HIV sexually:\n\n1. **HPTN 052:** 96% reduction in transmission with early ART\n2. **PARTNER 1 & 2:** Zero transmissions among ~77,000 condomless sex acts with undetectable partners\n3. **Opposites Attract:** Zero transmissions in gay male serodiscordant couples\n\n**For Your Patient (5 Years Undetectable):**\n- Their sustained viral suppression means transmission risk is effectively **zero**\n- U=U is recognized by CDC, WHO, UNAIDS, and all major health organizations\n- This applies to vaginal, anal, and oral sex\n\n**Is PrEP Recommended for Their Partner?**\n\n**If the partner's only HIV exposure is this relationship:**\n- PrEP is **not medically necessary** given U=U\n- The risk is already zero with sustained viral suppression\n\n**However, PrEP may still be considered if:**\n1. Partner has anxiety that affects relationship/intimacy\n2. Partner has other potential HIV exposures outside relationship\n3. Partner desires extra reassurance during any viral load fluctuations\n4. Personal preference for redundant protection\n\n**Key Counseling Points:**\n\n**For the HIV-positive patient:**\n- Reinforce that U=U is proven science, not a hope\n- Their consistent medication adherence protects their partner\n- They should feel proud and confident\n\n**For the HIV-negative partner:**\n- U=U is scientifically proven with zero transmissions in studies\n- PrEP is an option but not medically required\n- Decision should be based on their comfort, not fear\n- If PrEP provides peace of mind, that's a valid reason\n\n**Practical Recommendation:**\n1. Affirm U=U science to both partners\n2. Assess partner's other potential exposures\n3. Discuss partner's anxiety/comfort level\n4. Offer PrEP if desired, but don't push if not needed\n5. Regular viral load monitoring maintains confidence\n\n**Bottom Line:** PrEP adds no additional protection when the HIV-positive partner is truly undetectable, but it remains an option for psychological comfort or if there are other exposure risks.", "metadata": {"category": "clinical", "condition": "HIV_prevention", "severity": "low", "evidence_level": "guideline", "clinical_domain": "serodiscordant_couples", "source": "synthetic"}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient asking about PrEP for their HIV-negative partner. The patient has been undetectable for 5 years. Is PrEP still recommended?", "output": "This is a great question that reflects how well-informed your patients are about HIV prevention! Let me provide a comprehensive answer.\n\n**The Science: U=U (Undetectable = Untransmittable)**\n\nThree landmark studies definitively proved that people with sustained undetectable viral loads cannot transmit HIV sexually:\n\n1. **HPTN 052:** 96% reduction in transmission with early ART\n2. **PARTNER 1 & 2:** Zero transmissions among ~77,000 condomless sex acts with undetectable partners\n3. **Opposites Attract:** Zero transmissions in gay female serodiscordant couples\n\n**For Your Patient (5 Years Undetectable):**\n- Their sustained viral suppression means transmission risk is effectively **zero**\n- U=U is recognized by CDC, WHO, UNAIDS, and all major health organizations\n- This applies to vaginal, anal, and oral sex\n\n**Is PrEP Recommended for Their Partner?**\n\n**If the partner's only HIV exposure is this relationship:**\n- PrEP is **not medically necessary** given U=U\n- The risk is already zero with sustained viral suppression\n\n**However, PrEP may still be considered if:**\n1. Partner has anxiety that affects relationship/intimacy\n2. Partner has other potential HIV exposures outside relationship\n3. Partner desires extra reassurance during any viral load fluctuations\n4. Personal preference for redundant protection\n\n**Key Counseling Points:**\n\n**For the HIV-positive patient:**\n- Reinforce that U=U is proven science, not a hope\n- Their consistent medication adherence protects their partner\n- They should feel proud and confident\n\n**For the HIV-negative partner:**\n- U=U is scientifically proven with zero transmissions in studies\n- PrEP is an option but not medically required\n- Decision should be based on their comfort, not fear\n- If PrEP provides peace of mind, that's a valid reason\n\n**Practical Recommendation:**\n1. Affirm U=U science to both partners\n2. Assess partner's other potential exposures\n3. Discuss partner's anxiety/comfort level\n4. Offer PrEP if desired, but don't push if not needed\n5. Regular viral load monitoring maintains confidence\n\n**Bottom Line:** PrEP adds no additional protection when the HIV-positive partner is truly undetectable, but it remains an option for psychological comfort or if there are other exposure risks.", "metadata": {"category": "clinical", "condition": "HIV_prevention", "severity": "low", "evidence_level": "guideline", "clinical_domain": "serodiscordant_couples", "source": "synthetic_balanced", "gender_balanced": true}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient with multidrug resistant HIV. Previous regimens: TDF/FTC/EFV (failed), ABC/3TC/ATV/r (failed), RAL + DRV/r + ETR (failed). Genotype shows: K103N, M184V, K65R, L74V, Y181C, G190A, M46I, I84V, N155H, Q148H + G140S. What options remain?", "output": "This is a complex case of extensive multi-class resistance requiring careful construction of a salvage regimen. Let's analyze systematically.\n\n**Resistance Analysis:**\n\n**NRTI Resistance:**\n- M184V: High-level 3TC/FTC resistance\n- K65R: TDF, TAF, ABC resistance\n- L74V: ABC, ddI resistance\n- **Remaining NRTI activity:** Possibly TAF with reduced activity; consider keeping for partial activity + maintaining M184V (reduces viral fitness)\n\n**NNRTI Resistance:**\n- K103N, Y181C, G190A: Pan-NNRTI resistance\n- **NNRTI class:** No remaining options including doravirine\n\n**PI Resistance:**\n- M46I, I84V: Multi-PI resistance\n- **Boosted DRV:** May have reduced activity but worth including\n- Consider DRV 600mg BID (higher dose) with ritonavir\n\n**INSTI Resistance:**\n- N155H: RAL resistance, DTG susceptible\n- Q148H + G140S: This combination confers high-level resistance to RAL, EVG, AND reduces DTG activity significantly\n- **Remaining INSTI options:** Requires newer agents\n\n**Salvage Regimen Construction:**\n\n**Core Strategy: Build around 2+ fully active agents**\n\n**Recommended Regimen:**\n\n1. **Ibalizumab (Trogarzo)** - CD4-directed post-attachment inhibitor\n   - IV infusion every 2 weeks\n   - No cross-resistance with other classes\n   - Fully active\n\n2. **Fostemsavir (Rukobia)** - Attachment inhibitor (gp120-directed)\n   - 600mg BID\n   - Check fostemsavir susceptibility (env tropism)\n   - Novel mechanism, likely fully active\n\n3. **Lenacapavir (Sunlenca)** - First-in-class capsid inhibitor\n   - Subcutaneous every 6 months (after oral lead-in)\n   - Novel mechanism, no cross-resistance\n   - Likely fully active\n\n4. **Consider adding for partial activity:**\n   - DRV 600mg BID + ritonavir (may have partial activity)\n   - TAF or TDF (maintains M184V fitness cost, some residual activity)\n\n**Alternative if Lenacapavir Unavailable:**\n- Dolutegravir 50mg BID (doubled dosing may overcome some resistance)\n- Higher DTG doses being studied for Q148+G140S\n\n**Proposed Regimen:**\n```\nLenacapavir (q6 month) + Ibalizumab (q2 week) + Fostemsavir 600mg BID\n± DRV 600mg BID/r + TAF (background partial activity)\n```\n\n**Pre-Treatment:**\n1. Tropism testing for fostemsavir (not CCR5 tropism)\n2. Current viral load and CD4\n3. Hepatic function (fostemsavir monitoring)\n4. Insurance/access verification (specialty medications)\n\n**Monitoring:**\n- Viral load at 4, 8, 12 weeks, then quarterly\n- Goal: Undetectable achievable even with this resistance profile\n- Close adherence support\n\n**Access Considerations:**\n- Expanded access/compassionate use if needed\n- Patient assistance programs\n- Specialty pharmacy coordination\n\n**Prognosis:**\nWith modern salvage agents, viral suppression is achievable even in this heavily treatment-experienced scenario. These newer drugs have demonstrated efficacy in patients with extensive resistance.", "metadata": {"category": "clinical", "condition": "HIV_multidrug_resistance", "severity": "critical", "evidence_level": "guideline", "clinical_domain": "salvage_therapy", "source": "synthetic"}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient with multidrug resistant HIV. Previous regimens: TDF/FTC/EFV (failed), ABC/3TC/ATV/r (failed), RAL + DRV/r + ETR (failed). Genotype shows: K103N, M184V, K65R, L74V, Y181C, G190A, M46I, I84V, N155H, Q148H + G140S. What options remain?", "output": "This is a complex case of extensive multi-class resistance requiring careful construction of a salvage regimen. Let's analyze systematically.\n\n**Resistance Analysis:**\n\n**NRTI Resistance:**\n- M184V: High-level 3TC/FTC resistance\n- K65R: TDF, TAF, ABC resistance\n- L74V: ABC, ddI resistance\n- **Remaining NRTI activity:** Possibly TAF with reduced activity; consider keeping for partial activity + maintaining M184V (reduces viral fitness)\n\n**NNRTI Resistance:**\n- K103N, Y181C, G190A: Pan-NNRTI resistance\n- **NNRTI class:** No remaining options including doravirine\n\n**PI Resistance:**\n- M46I, I84V: Multi-PI resistance\n- **Boosted DRV:** May have reduced activity but worth including\n- Consider DRV 600mg BID (higher dose) with ritonavir\n\n**INSTI Resistance:**\n- N155H: RAL resistance, DTG susceptible\n- Q148H + G140S: This combination confers high-level resistance to RAL, EVG, AND reduces DTG activity significantly\n- **Remaining INSTI options:** Requires newer agents\n\n**Salvage Regimen Construction:**\n\n**Core Strategy: Build around 2+ fully active agents**\n\n**Recommended Regimen:**\n\n1. **Ibalizumab (Trogarzo)** - CD4-directed post-attachment inhibitor\n   - IV infusion every 2 weeks\n   - No cross-resistance with other classes\n   - Fully active\n\n2. **Fostemsavir (Rukobia)** - Attachment inhibitor (gp120-directed)\n   - 600mg BID\n   - Check fostemsavir susceptibility (env tropism)\n   - Novel mechanism, likely fully active\n\n3. **Lenacapavir (Sunlenca)** - First-in-class capsid inhibitor\n   - Subcutaneous every 6 months (after oral lead-in)\n   - Novel mechanism, no cross-resistance\n   - Likely fully active\n\n4. **Consider adding for partial activity:**\n   - DRV 600mg BID + ritonavir (may have partial activity)\n   - TAF or TDF (maintains M184V fitness cost, some residual activity)\n\n**Alternative if Lenacapavir Unavailable:**\n- Dolutegravir 50mg BID (doubled dosing may overcome some resistance)\n- Higher DTG doses being studied for Q148+G140S\n\n**Proposed Regimen:**\n```\nLenacapavir (q6 month) + Ibalizumab (q2 week) + Fostemsavir 600mg BID\n± DRV 600mg BID/r + TAF (background partial activity)\n```\n\n**Pre-Treatment:**\n1. Tropism testing for fostemsavir (not CCR5 tropism)\n2. Current viral load and CD4\n3. Hepatic function (fostemsavir monitoring)\n4. Insurance/access verification (specialty medications)\n\n**Monitoring:**\n- Viral load at 4, 8, 12 weeks, then quarterly\n- Goal: Undetectable achievable even with this resistance profile\n- Close adherence support\n\n**Access Considerations:**\n- Expanded access/compassionate use if needed\n- Patient assistance programs\n- Specialty pharmacy coordination\n\n**Prognosis:**\nWith modern salvage agents, viral suppression is achievable even in this heavily treatment-experienced scenario. These newer drugs have demonstrated efficacy in patients with extensive resistance.", "metadata": {"category": "clinical", "condition": "HIV_multidrug_resistance", "severity": "critical", "evidence_level": "guideline", "clinical_domain": "salvage_therapy", "source": "synthetic_balanced", "gender_balanced": true}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient interested in switching to long-acting injectable HIV treatment. Currently on Biktarvy, undetectable for 2 years. CD4 720. No resistance history. Is this a good candidate?", "output": "This patient is an excellent candidate for long-acting injectable antiretroviral therapy (LA-ART). Let me outline the assessment and transition process.\n\n**Candidate Assessment - This Patient:**\n\n**Favorable Factors:**\n- Virally suppressed for 2+ years (required)\n- No known resistance mutations (critical)\n- Treatment-naive to cabotegravir and rilpivirine\n- Stable CD4 count (720)\n- Currently on single-tablet regimen (good adherence suggested)\n\n**Available Long-Acting Options:**\n\n**1. Cabenuva (Cabotegravir + Rilpivirine LA)**\n- Two intramuscular injections\n- Every 2 months (after initial monthly x2) OR monthly dosing\n- Administered by healthcare provider\n- FDA approved, well-established\n\n**Pre-Switch Requirements:**\n\n**1. Resistance Testing:**\n- Historical genotype if available\n- Specifically need to confirm no NNRTI resistance (for rilpivirine)\n- Key mutations to exclude: K101E/P, E138A/G/K/Q/R, Y181C/I/V, H221Y, M230I/L\n\n**2. Hepatitis B Status:**\n- Must check HBsAg\n- If HBV positive: Cannot stop tenofovir-containing regimen without HBV flare risk\n\n**3. Oral Lead-In (Optional but Recommended):**\n- Cabotegravir 30mg + Rilpivirine 25mg daily x 4 weeks\n- Confirms tolerability before committing to LA injections\n\n**Transition Protocol:**\n\n**Week 0:** Start oral lead-in, stop Biktarvy same day\n**Week 4:** If tolerating oral, initiate injections\n**Ongoing:** Continue per chosen schedule (monthly or every 2 months)\n\n**Patient Counseling Points:**\n\n**Benefits:**\n- No daily pills\n- Improved privacy (no pill bottles)\n- Eliminates daily adherence burden\n\n**Considerations:**\n- Requires clinic visits every 1-2 months\n- Injection site reactions are common (usually mild)\n- Cannot stop immediately if side effects (drug persists)\n\n**This Patient's Bottom Line:**\nExcellent candidate. Proceed with HBV testing and resistance review. If no contraindications, offer oral lead-in followed by Cabenuva initiation.", "metadata": {"category": "clinical", "condition": "HIV", "severity": "low", "evidence_level": "guideline", "clinical_domain": "long_acting_therapy", "source": "synthetic"}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient interested in switching to long-acting injectable HIV treatment. Currently on Biktarvy, undetectable for 2 years. CD4 720. No resistance history. Is this a good candidate?", "output": "This patient is an excellent candidate for long-acting injectable antiretroviral therapy (LA-ART). Let me outline the assessment and transition process.\n\n**Candidate Assessment - This Patient:**\n\n**Favorable Factors:**\n- Virally suppressed for 2+ years (required)\n- No known resistance mutations (critical)\n- Treatment-naive to cabotegravir and rilpivirine\n- Stable CD4 count (720)\n- Currently on single-tablet regimen (good adherence suggested)\n\n**Available Long-Acting Options:**\n\n**1. Cabenuva (Cabotegravir + Rilpivirine LA)**\n- Two intramuscular injections\n- Every 2 months (after initial monthly x2) OR monthly dosing\n- Administered by healthcare provider\n- FDA approved, well-established\n\n**Pre-Switch Requirements:**\n\n**1. Resistance Testing:**\n- Historical genotype if available\n- Specifically need to confirm no NNRTI resistance (for rilpivirine)\n- Key mutations to exclude: K101E/P, E138A/G/K/Q/R, Y181C/I/V, H221Y, M230I/L\n\n**2. Hepatitis B Status:**\n- Must check HBsAg\n- If HBV positive: Cannot stop tenofovir-containing regimen without HBV flare risk\n\n**3. Oral Lead-In (Optional but Recommended):**\n- Cabotegravir 30mg + Rilpivirine 25mg daily x 4 weeks\n- Confirms tolerability before committing to LA injections\n\n**Transition Protocol:**\n\n**Week 0:** Start oral lead-in, stop Biktarvy same day\n**Week 4:** If tolerating oral, initiate injections\n**Ongoing:** Continue per chosen schedule (monthly or every 2 months)\n\n**Patient Counseling Points:**\n\n**Benefits:**\n- No daily pills\n- Improved privacy (no pill bottles)\n- Eliminates daily adherence burden\n\n**Considerations:**\n- Requires clinic visits every 1-2 months\n- Injection site reactions are common (usually mild)\n- Cannot stop immediately if side effects (drug persists)\n\n**This Patient's Bottom Line:**\nExcellent candidate. Proceed with HBV testing and resistance review. If no contraindications, offer oral lead-in followed by Cabenuva initiation.", "metadata": {"category": "clinical", "condition": "HIV", "severity": "low", "evidence_level": "guideline", "clinical_domain": "long_acting_therapy", "source": "synthetic_balanced", "gender_balanced": true}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient with HIV presents with white patches on tongue and difficulty swallowing. CD4 is 85, viral load 120,000. Recently diagnosed, not yet on treatment. What's the diagnosis and management?", "output": "This presentation is highly concerning for oropharyngeal and likely esophageal candidiasis in the setting of advanced HIV/AIDS.\n\n**Clinical Assessment:**\n\n**Diagnosis: Oropharyngeal Candidiasis (Thrush) ± Esophageal Candidiasis**\n\n- White patches on tongue = classic thrush appearance\n- Difficulty swallowing (dysphagia) = suggests esophageal involvement\n- CD4 85 = severe immunosuppression (AIDS)\n- Esophageal candidiasis is an AIDS-defining illness\n\n**Immediate Treatment:**\n\n**For Oropharyngeal Candidiasis:**\n- First-line: Fluconazole 100-200mg PO daily x 7-14 days\n\n**For Esophageal Candidiasis:**\n- Required: Fluconazole 200-400mg PO daily x 14-21 days\n\n**Recommended:** Start fluconazole 200mg daily for presumed esophageal involvement given dysphagia.\n\n**Opportunistic Infection Prophylaxis (CD4 <200):**\n- Start TMP-SMX DS daily for PCP prophylaxis immediately\n\n**Additional Workup:**\n- TB screening (PPD or IGRA)\n- Toxoplasma IgG\n- CMV IgG\n- Cryptococcal antigen (CD4 <100)\n- Baseline resistance genotype\n\n**ART Initiation:**\n- Can start ART within 2 weeks of initiating OI treatment\n- Recommended ART: Biktarvy or Triumeq\n- IRIS risk with candidiasis is low\n\n**Prognosis:**\nWith treatment of candidiasis and initiation of ART, expect rapid improvement. CD4 recovery will prevent future opportunistic infections.", "metadata": {"category": "clinical", "condition": "HIV_opportunistic_infection", "severity": "high", "evidence_level": "guideline", "clinical_domain": "opportunistic_infections", "source": "synthetic"}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient with HIV presents with white patches on tongue and difficulty swallowing. CD4 is 85, viral load 120,000. Recently diagnosed, not yet on treatment. What's the diagnosis and management?", "output": "This presentation is highly concerning for oropharyngeal and likely esophageal candidiasis in the setting of advanced HIV/AIDS.\n\n**Clinical Assessment:**\n\n**Diagnosis: Oropharyngeal Candidiasis (Thrush) ± Esophageal Candidiasis**\n\n- White patches on tongue = classic thrush appearance\n- Difficulty swallowing (dysphagia) = suggests esophageal involvement\n- CD4 85 = severe immunosuppression (AIDS)\n- Esophageal candidiasis is an AIDS-defining illness\n\n**Immediate Treatment:**\n\n**For Oropharyngeal Candidiasis:**\n- First-line: Fluconazole 100-200mg PO daily x 7-14 days\n\n**For Esophageal Candidiasis:**\n- Required: Fluconazole 200-400mg PO daily x 14-21 days\n\n**Recommended:** Start fluconazole 200mg daily for presumed esophageal involvement given dysphagia.\n\n**Opportunistic Infection Prophylaxis (CD4 <200):**\n- Start TMP-SMX DS daily for PCP prophylaxis immediately\n\n**Additional Workup:**\n- TB screening (PPD or IGRA)\n- Toxoplasma IgG\n- CMV IgG\n- Cryptococcal antigen (CD4 <100)\n- Baseline resistance genotype\n\n**ART Initiation:**\n- Can start ART within 2 weeks of initiating OI treatment\n- Recommended ART: Biktarvy or Triumeq\n- IRIS risk with candidiasis is low\n\n**Prognosis:**\nWith treatment of candidiasis and initiation of ART, expect rapid improvement. CD4 recovery will prevent future opportunistic infections.", "metadata": {"category": "clinical", "condition": "HIV_opportunistic_infection", "severity": "high", "evidence_level": "guideline", "clinical_domain": "opportunistic_infections", "source": "synthetic_balanced", "gender_balanced": true}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Adolescent patient, 16 years old, wants to start HIV treatment but parents don't know about the diagnosis. Can we treat without parental consent?", "output": "This is a complex situation involving minor consent, confidentiality, and urgent medical need.\n\n**Legal Framework - Minor Consent for HIV:**\n\n**Good News:** In most US states, minors can consent to HIV testing and treatment without parental involvement.\n\n**State Laws Generally Allow:**\n- STI testing and treatment at any age (HIV usually included)\n- Many states specifically address HIV\n- Some states have explicit 'mature minor' doctrines\n\n**Action Required:**\n- Verify your specific state's minor consent laws\n- Consult with clinic legal/compliance team\n\n**Clinical Priority - Treat Now:**\n- HIV is a serious condition requiring prompt ART\n- Delaying treatment harms the patient\n- Their autonomy and confidentiality should be respected\n\n**Confidentiality Protections:**\n\n**Insurance Considerations:**\n- If on parent's insurance, EOBs may reveal visits/claims\n- Consider Ryan White/ADAP for medication coverage (confidential)\n- Patient assistance programs\n\n**Practical Strategies for Confidentiality:**\n- Use patient's cell phone for contact\n- Discuss medication storage options\n- Some patients keep medications at trusted friend's house\n- Clinic can hold medications for pick-up\n\n**Safety Assessment:**\n- Is the patient safe at home?\n- Any concerns about abuse or neglect?\n- Were there any concerning circumstances around HIV acquisition?\n\n**Recommended Approach:**\n1. Affirm their decision to seek care\n2. Confirm state law allows treatment without parental consent\n3. Initiate ART promptly\n4. Establish confidential communication methods\n5. Connect to adolescent-focused HIV services\n6. Explore (gently) disclosure possibilities over time", "metadata": {"category": "clinical", "condition": "HIV", "severity": "high", "evidence_level": "expert_consensus", "clinical_domain": "adolescent_care", "source": "synthetic"}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Adolescent patient, 16 years old, wants to start HIV treatment but parents don't know about the diagnosis. Can we treat without parental consent?", "output": "This is a complex situation involving minor consent, confidentiality, and urgent medical need.\n\n**Legal Framework - Minor Consent for HIV:**\n\n**Good News:** In most US states, minors can consent to HIV testing and treatment without parental involvement.\n\n**State Laws Generally Allow:**\n- STI testing and treatment at any age (HIV usually included)\n- Many states specifically address HIV\n- Some states have explicit 'mature minor' doctrines\n\n**Action Required:**\n- Verify your specific state's minor consent laws\n- Consult with clinic legal/compliance team\n\n**Clinical Priority - Treat Now:**\n- HIV is a serious condition requiring prompt ART\n- Delaying treatment harms the patient\n- Their autonomy and confidentiality should be respected\n\n**Confidentiality Protections:**\n\n**Insurance Considerations:**\n- If on parent's insurance, EOBs may reveal visits/claims\n- Consider Ryan White/ADAP for medication coverage (confidential)\n- Patient assistance programs\n\n**Practical Strategies for Confidentiality:**\n- Use patient's cell phone for contact\n- Discuss medication storage options\n- Some patients keep medications at trusted friend's house\n- Clinic can hold medications for pick-up\n\n**Safety Assessment:**\n- Is the patient safe at home?\n- Any concerns about abuse or neglect?\n- Were there any concerning circumstances around HIV acquisition?\n\n**Recommended Approach:**\n1. Affirm their decision to seek care\n2. Confirm state law allows treatment without parental consent\n3. Initiate ART promptly\n4. Establish confidential communication methods\n5. Connect to adolescent-focused HIV services\n6. Explore (gently) disclosure possibilities over time", "metadata": {"category": "clinical", "condition": "HIV", "severity": "high", "evidence_level": "expert_consensus", "clinical_domain": "adolescent_care", "source": "synthetic_balanced", "gender_balanced": true}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient on Genvoya develops acute kidney injury. Creatinine went from 1.0 to 2.8 over 3 months. They also have hypertension treated with lisinopril. What's happening?", "output": "This is a significant acute kidney injury (AKI) that requires immediate evaluation and likely ARV modification.\n\n**Potential Causes:**\n\n**1. Tenofovir (TAF) Nephrotoxicity:**\n- Genvoya contains TAF (tenofovir alafenamide)\n- TAF is less nephrotoxic than TDF, but proximal tubular toxicity still possible\n\n**2. Cobicistat Drug Interaction:**\n- Genvoya contains cobicistat as pharmacokinetic booster\n- Cobicistat inhibits tubular secretion of creatinine\n- Typically raises creatinine by 0.1-0.15 (not 1.8!)\n- This magnitude suggests true GFR decline\n\n**3. ACE-I/ARB Effect:**\n- Lisinopril can cause creatinine rise, especially if volume depleted\n\n**Recommended Workup:**\n- Comprehensive metabolic panel\n- Urinalysis with microscopy\n- Urine protein/creatinine ratio\n- Urine glucose (tubular dysfunction)\n- Serum phosphorus\n- Renal ultrasound\n\n**Immediate Actions:**\n\n**1. SWITCH ARV:**\n- Stop Genvoya immediately\n- Switch to TAF-free, TDF-free regimen\n- Recommended: Dolutegravir + Lamivudine (Dovato)\n  - No tenofovir component\n  - No cobicistat\n  - Renally safe\n\n**2. Hold Lisinopril Temporarily:**\n- Until creatinine stabilizes\n- Alternative BP agent if needed (CCB)\n\n**3. Avoid Nephrotoxins:**\n- No NSAIDs\n- Avoid contrast if possible\n\n**Monitoring:**\n- Repeat creatinine in 3-5 days\n- If improving: Continue new regimen, monitor weekly\n- If worsening: Nephrology referral urgent\n\n**Expected Course:**\n- If tenofovir-related, creatinine should improve after stopping\n- Recovery may take weeks to months\n\n**Key Point:** Don't delay the ARV switch.", "metadata": {"category": "clinical", "condition": "HIV_renal_toxicity", "severity": "high", "evidence_level": "guideline", "clinical_domain": "adverse_events", "source": "synthetic"}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient on Genvoya develops acute kidney injury. Creatinine went from 1.0 to 2.8 over 3 months. They also have hypertension treated with lisinopril. What's happening?", "output": "This is a significant acute kidney injury (AKI) that requires immediate evaluation and likely ARV modification.\n\n**Potential Causes:**\n\n**1. Tenofovir (TAF) Nephrotoxicity:**\n- Genvoya contains TAF (tenofovir alafenamide)\n- TAF is less nephrotoxic than TDF, but proximal tubular toxicity still possible\n\n**2. Cobicistat Drug Interaction:**\n- Genvoya contains cobicistat as pharmacokinetic booster\n- Cobicistat inhibits tubular secretion of creatinine\n- Typically raises creatinine by 0.1-0.15 (not 1.8!)\n- This magnitude suggests true GFR decline\n\n**3. ACE-I/ARB Effect:**\n- Lisinopril can cause creatinine rise, especially if volume depleted\n\n**Recommended Workup:**\n- Comprehensive metabolic panel\n- Urinalysis with microscopy\n- Urine protein/creatinine ratio\n- Urine glucose (tubular dysfunction)\n- Serum phosphorus\n- Renal ultrasound\n\n**Immediate Actions:**\n\n**1. SWITCH ARV:**\n- Stop Genvoya immediately\n- Switch to TAF-free, TDF-free regimen\n- Recommended: Dolutegravir + Lamivudine (Dovato)\n  - No tenofovir component\n  - No cobicistat\n  - Renally safe\n\n**2. Hold Lisinopril Temporarily:**\n- Until creatinine stabilizes\n- Alternative BP agent if needed (CCB)\n\n**3. Avoid Nephrotoxins:**\n- No NSAIDs\n- Avoid contrast if possible\n\n**Monitoring:**\n- Repeat creatinine in 3-5 days\n- If improving: Continue new regimen, monitor weekly\n- If worsening: Nephrology referral urgent\n\n**Expected Course:**\n- If tenofovir-related, creatinine should improve after stopping\n- Recovery may take weeks to months\n\n**Key Point:** Don't delay the ARV switch.", "metadata": {"category": "clinical", "condition": "HIV_renal_toxicity", "severity": "high", "evidence_level": "guideline", "clinical_domain": "adverse_events", "source": "synthetic_balanced", "gender_balanced": true}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient reports significant weight gain (30 lbs in 18 months) since switching to an integrase inhibitor-based regimen. Now BMI is 34. They're frustrated and considering stopping HIV medication. How should we address this?", "output": "Weight gain associated with integrase inhibitors (INSTIs) is a real and increasingly recognized concern that deserves thoughtful attention.\n\n**Acknowledging the Problem:**\n\n- INSTI-associated weight gain is real and documented\n- 30 lbs is significant and impacts health and quality of life\n- Their frustration is understandable\n\n**The Evidence on INSTIs and Weight Gain:**\n\n- Weight gain occurs with most ARV regimens after treatment initiation\n- INSTIs (especially dolutegravir, bictegravir) associated with more weight gain\n- TAF associated with more weight gain than TDF\n- Effect appears greater in women and Black patients\n\n**Approach to Management:**\n\n**Step 1: Complete Assessment**\n- Rule out thyroid dysfunction, diabetes\n- Review other medications causing weight gain\n- Document weight trajectory\n\n**Step 2: Discuss Options**\n\n**Option A: Lifestyle Intervention First**\n- Dietary counseling, exercise program\n- Trial period: 3-6 months\n\n**Option B: ARV Switch to Weight-Neutral Option**\n- Doravirine (NNRTI) - weight neutral in studies\n- Must check resistance history\n- Some evidence for weight loss after switching from INSTI\n\n**Option C: Pharmacologic Weight Loss**\n- GLP-1 agonists (Semaglutide, Tirzepatide)\n- Significant weight loss potential\n- No major ARV interactions\n\n**Critical Counseling:**\n\n**Do NOT Stop HIV Medication:**\n- Stopping treatment leads to viral rebound\n- Resistance can develop\n- Health consequences of untreated HIV exceed weight gain\n- There are solutions that don't require stopping treatment\n\n**Recommended Plan:**\n1. Complete metabolic workup\n2. Review resistance history for switch options\n3. If switching: Doravirine + TDF/FTC\n4. Monitor weight monthly for 3 months\n\n**Key Message:** Weight gain is a valid concern with solutions. Stopping HIV treatment entirely is not one of them.", "metadata": {"category": "clinical", "condition": "HIV", "severity": "medium", "evidence_level": "guideline", "clinical_domain": "adverse_events", "source": "synthetic"}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient reports significant weight gain (30 lbs in 18 months) since switching to an integrase inhibitor-based regimen. Now BMI is 34. They're frustrated and considering stopping HIV medication. How should we address this?", "output": "Weight gain associated with integrase inhibitors (INSTIs) is a real and increasingly recognized concern that deserves thoughtful attention.\n\n**Acknowledging the Problem:**\n\n- INSTI-associated weight gain is real and documented\n- 30 lbs is significant and impacts health and quality of life\n- Their frustration is understandable\n\n**The Evidence on INSTIs and Weight Gain:**\n\n- Weight gain occurs with most ARV regimens after treatment initiation\n- INSTIs (especially dolutegravir, bictegravir) associated with more weight gain\n- TAF associated with more weight gain than TDF\n- Effect appears greater in women and Black patients\n\n**Approach to Management:**\n\n**Step 1: Complete Assessment**\n- Rule out thyroid dysfunction, diabetes\n- Review other medications causing weight gain\n- Document weight trajectory\n\n**Step 2: Discuss Options**\n\n**Option A: Lifestyle Intervention First**\n- Dietary counseling, exercise program\n- Trial period: 3-6 months\n\n**Option B: ARV Switch to Weight-Neutral Option**\n- Doravirine (NNRTI) - weight neutral in studies\n- Must check resistance history\n- Some evidence for weight loss after switching from INSTI\n\n**Option C: Pharmacologic Weight Loss**\n- GLP-1 agonists (Semaglutide, Tirzepatide)\n- Significant weight loss potential\n- No major ARV interactions\n\n**Critical Counseling:**\n\n**Do NOT Stop HIV Medication:**\n- Stopping treatment leads to viral rebound\n- Resistance can develop\n- Health consequences of untreated HIV exceed weight gain\n- There are solutions that don't require stopping treatment\n\n**Recommended Plan:**\n1. Complete metabolic workup\n2. Review resistance history for switch options\n3. If switching: Doravirine + TDF/FTC\n4. Monitor weight monthly for 3 months\n\n**Key Message:** Weight gain is a valid concern with solutions. Stopping HIV treatment entirely is not one of them.", "metadata": {"category": "clinical", "condition": "HIV", "severity": "medium", "evidence_level": "guideline", "clinical_domain": "adverse_events", "source": "synthetic_balanced", "gender_balanced": true}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient with well-controlled HIV on Dovato (dolutegravir/lamivudine two-drug regimen) is now found to have hepatitis B coinfection. HBsAg positive, HBV DNA 150,000 IU/mL. How should we manage this?", "output": "This is a critical finding that requires immediate regimen modification. Dovato is not appropriate for HIV/HBV coinfection.\n\n**The Problem:**\n\n**Dovato Contains:**\n- Dolutegravir (DTG) - no HBV activity\n- Lamivudine (3TC) - Has HBV activity BUT:\n  - Weak HBV suppression as monotherapy\n  - High rate of HBV resistance development\n  - 3TC monotherapy for HBV is NOT adequate\n\n**Required Action: Switch Regimen**\n\n**Recommended New Regimen:**\n\n**Option 1 (Preferred): Biktarvy**\n- Bictegravir/Tenofovir AF/Emtricitabine\n- TAF + FTC provide dual HBV coverage\n- Single tablet, once daily\n\n**Why TAF/FTC for HBV:**\n- Tenofovir is first-line HBV therapy (potent, low resistance)\n- Emtricitabine adds second HBV-active agent\n- Dual coverage superior to 3TC alone\n\n**Transition Plan:**\n\n**Day 1:**\n- Stop Dovato\n- Start Biktarvy\n- Same day switch (no gap needed)\n\n**Do NOT:**\n- Stop lamivudine without starting another HBV-active regimen\n- This can cause severe hepatic flare (HBV reactivation)\n\n**Monitoring:**\n\n**Initial Workup:**\n- HBeAg, Anti-HBe\n- Liver panel\n- AFP (HCC screening)\n- Liver ultrasound\n- FibroScan for fibrosis assessment\n\n**Follow-up Schedule:**\n- HBV DNA at 4 weeks, 12 weeks, then every 3-6 months\n- Goal: HBV DNA undetectable\n- Ultrasound every 6 months for HCC surveillance\n\n**Long-term:**\n- HBV requires lifelong treatment (like HIV)\n- Cannot stop tenofovir-containing regimen without HBV flare risk\n- Future regimen changes must maintain HBV coverage", "metadata": {"category": "clinical", "condition": "HIV_HBV_coinfection", "severity": "high", "evidence_level": "guideline", "clinical_domain": "coinfection_management", "source": "synthetic"}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient with well-controlled HIV on Dovato (dolutegravir/lamivudine two-drug regimen) is now found to have hepatitis B coinfection. HBsAg positive, HBV DNA 150,000 IU/mL. How should we manage this?", "output": "This is a critical finding that requires immediate regimen modification. Dovato is not appropriate for HIV/HBV coinfection.\n\n**The Problem:**\n\n**Dovato Contains:**\n- Dolutegravir (DTG) - no HBV activity\n- Lamivudine (3TC) - Has HBV activity BUT:\n  - Weak HBV suppression as monotherapy\n  - High rate of HBV resistance development\n  - 3TC monotherapy for HBV is NOT adequate\n\n**Required Action: Switch Regimen**\n\n**Recommended New Regimen:**\n\n**Option 1 (Preferred): Biktarvy**\n- Bictegravir/Tenofovir AF/Emtricitabine\n- TAF + FTC provide dual HBV coverage\n- Single tablet, once daily\n\n**Why TAF/FTC for HBV:**\n- Tenofovir is first-line HBV therapy (potent, low resistance)\n- Emtricitabine adds second HBV-active agent\n- Dual coverage superior to 3TC alone\n\n**Transition Plan:**\n\n**Day 1:**\n- Stop Dovato\n- Start Biktarvy\n- Same day switch (no gap needed)\n\n**Do NOT:**\n- Stop lamivudine without starting another HBV-active regimen\n- This can cause severe hepatic flare (HBV reactivation)\n\n**Monitoring:**\n\n**Initial Workup:**\n- HBeAg, Anti-HBe\n- Liver panel\n- AFP (HCC screening)\n- Liver ultrasound\n- FibroScan for fibrosis assessment\n\n**Follow-up Schedule:**\n- HBV DNA at 4 weeks, 12 weeks, then every 3-6 months\n- Goal: HBV DNA undetectable\n- Ultrasound every 6 months for HCC surveillance\n\n**Long-term:**\n- HBV requires lifelong treatment (like HIV)\n- Cannot stop tenofovir-containing regimen without HBV flare risk\n- Future regimen changes must maintain HBV coverage", "metadata": {"category": "clinical", "condition": "HIV_HBV_coinfection", "severity": "high", "evidence_level": "guideline", "clinical_domain": "coinfection_management", "source": "synthetic_balanced", "gender_balanced": true}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient recently started on Biktarvy 2 weeks ago. Labs show creatinine increased from 0.9 to 1.1. Should I be concerned?", "output": "This is actually an expected finding with Biktarvy and does not represent true kidney injury.\n\n**What's Happening:**\n\n**Bictegravir (the INSTI in Biktarvy) inhibits tubular secretion of creatinine.**\n\nThis is a pharmacologic effect, not kidney damage:\n- Creatinine is secreted by renal tubules\n- Bictegravir inhibits OCT2 and MATE1 transporters\n- This reduces creatinine secretion\n- Serum creatinine rises slightly\n- But actual GFR is unchanged\n\n**Expected Magnitude:**\n- Creatinine increase of 0.1-0.15 mg/dL\n- This patient: 0.9 → 1.1 = 0.2 increase (within expected range)\n- Usually occurs in first 2-4 weeks\n- Plateaus and remains stable\n\n**This is NOT:**\n- True kidney injury\n- Reason to stop or change medication\n- Progressive (should not continue to rise)\n\n**Differentiation from True Kidney Injury:**\n\n| Feature | Creatinine Effect | True AKI |\n|---------|-------------------|----------|\n| Magnitude | 0.1-0.15 mg/dL | Often larger |\n| Timing | First 2-4 weeks | Variable |\n| Progression | Stable | May worsen |\n| Other markers | Normal | May be abnormal |\n| Urinalysis | Normal | May show protein, cells |\n\n**When to Be Concerned:**\n- Creatinine rise >0.3-0.4 mg/dL\n- Continued rise after initial plateau\n- New proteinuria\n- Electrolyte abnormalities\n- Symptoms (decreased urine output, edema)\n\n**Recommendations for This Patient:**\n\n1. **Reassurance:** This is expected and not harmful\n2. **Continue Biktarvy:** No change needed\n3. **Repeat creatinine:** In 4-6 weeks to confirm stability\n4. **Baseline for future:** Document new creatinine baseline (~1.1)\n5. **Monitor:** Per routine HIV care schedule\n\n**Patient Counseling:**\n\"Your creatinine went up slightly, but this is a known effect of your medication. It doesn't mean your kidneys are being damaged - it's just how the medication affects a lab test. We'll monitor it, but it should stay stable.\"", "metadata": {"category": "clinical", "condition": "HIV", "severity": "low", "evidence_level": "guideline", "clinical_domain": "lab_interpretation", "source": "synthetic"}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient recently started on Biktarvy 2 weeks ago. Labs show creatinine increased from 0.9 to 1.1. Should I be concerned?", "output": "This is actually an expected finding with Biktarvy and does not represent true kidney injury.\n\n**What's Happening:**\n\n**Bictegravir (the INSTI in Biktarvy) inhibits tubular secretion of creatinine.**\n\nThis is a pharmacologic effect, not kidney damage:\n- Creatinine is secreted by renal tubules\n- Bictegravir inhibits OCT2 and MATE1 transporters\n- This reduces creatinine secretion\n- Serum creatinine rises slightly\n- But actual GFR is unchanged\n\n**Expected Magnitude:**\n- Creatinine increase of 0.1-0.15 mg/dL\n- This patient: 0.9 → 1.1 = 0.2 increase (within expected range)\n- Usually occurs in first 2-4 weeks\n- Plateaus and remains stable\n\n**This is NOT:**\n- True kidney injury\n- Reason to stop or change medication\n- Progressive (should not continue to rise)\n\n**Differentiation from True Kidney Injury:**\n\n| Feature | Creatinine Effect | True AKI |\n|---------|-------------------|----------|\n| Magnitude | 0.1-0.15 mg/dL | Often larger |\n| Timing | First 2-4 weeks | Variable |\n| Progression | Stable | May worsen |\n| Other markers | Normal | May be abnormal |\n| Urinalysis | Normal | May show protein, cells |\n\n**When to Be Concerned:**\n- Creatinine rise >0.3-0.4 mg/dL\n- Continued rise after initial plateau\n- New proteinuria\n- Electrolyte abnormalities\n- Symptoms (decreased urine output, edema)\n\n**Recommendations for This Patient:**\n\n1. **Reassurance:** This is expected and not harmful\n2. **Continue Biktarvy:** No change needed\n3. **Repeat creatinine:** In 4-6 weeks to confirm stability\n4. **Baseline for future:** Document new creatinine baseline (~1.1)\n5. **Monitor:** Per routine HIV care schedule\n\n**Patient Counseling:**\n\"Your creatinine went up slightly, but this is a known effect of your medication. It doesn't mean your kidneys are being damaged - it's just how the medication affects a lab test. We'll monitor it, but it should stay stable.\"", "metadata": {"category": "clinical", "condition": "HIV", "severity": "low", "evidence_level": "guideline", "clinical_domain": "lab_interpretation", "source": "synthetic_balanced", "gender_balanced": true}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient with HIV controlled on Biktarvy for 5 years now has stage 4 CKD (eGFR 22). Nephrologist is concerned about continuing tenofovir. What are the options?", "output": "Stage 4 CKD (eGFR 22) requires careful ARV selection to avoid further renal injury while maintaining viral suppression.\n\n**Current Concern:**\n\n**Biktarvy contains TAF (tenofovir alafenamide):**\n- TAF is safer than TDF but still renally cleared\n- Not recommended below eGFR 30 in some guidelines\n- This patient is below that threshold\n- Nephrologist concern is valid\n\n**ARV Options for Advanced CKD:**\n\n**Option 1 (Preferred): Dolutegravir + Lamivudine (Dovato)**\n\n**Advantages:**\n- No tenofovir\n- DTG: Hepatic metabolism, safe in CKD\n- 3TC: Dose adjust for eGFR <50\n- Proven two-drug regimen\n\n**3TC Dosing in CKD:**\n- eGFR 30-49: 150mg daily\n- eGFR 15-29: 150mg first dose, then 100mg daily\n- eGFR <15: 150mg first dose, then 50mg daily\n\n**Important:** If HBV coinfection, cannot use Dovato (need HBV coverage)\n\n**Option 2: Dolutegravir + Rilpivirine (Juluca)**\n\n**Advantages:**\n- Two-drug regimen\n- Both hepatically metabolized\n- No dose adjustment for CKD\n\n**Disadvantages:**\n- Must take with food (400+ calories)\n- Need RPV resistance testing\n- Drug interactions (PPIs contraindicated)\n\n**Option 3: Dolutegravir monotherapy (Less preferred)**\n\n- Some data supports DTG monotherapy in suppressed patients\n- Not standard of care\n- Risk of resistance if adherence imperfect\n- Consider only if no other options\n\n**Pre-Switch Assessment:**\n\n1. **Hepatitis B status:**\n   - If HBsAg positive: Need HBV-active regimen\n   - Cannot use Dovato or Juluca alone\n   - Would need entecavir separately for HBV\n\n2. **Resistance history:**\n   - Check historical genotypes\n   - Confirm no INSTI or NNRTI resistance\n\n3. **Current viral suppression:**\n   - Confirm undetectable before switching\n\n**Recommended Approach:**\n\n```\nIf HBV negative:\n  Switch to Dovato (DTG/3TC) with 3TC dose adjusted for CKD\n  \nIf HBV positive:\n  Switch to DTG + 3TC (dose adjusted) + Entecavir\n  (Entecavir 0.5mg - also needs CKD dose adjustment)\n```\n\n**Monitoring After Switch:**\n- Viral load at 4 weeks\n- Renal function (already being monitored by nephrology)\n- HBV DNA if coinfected\n\n**Additional Considerations:**\n\n**Dialysis Planning:**\n- If progressing toward dialysis, some ARVs are dialyzable\n- DTG: Not significantly removed by dialysis\n- 3TC: Is removed - give dose after dialysis\n\n**Transplant Consideration:**\n- If transplant candidate, drug interactions will matter\n- DTG-based regimens generally preferred\n- Avoid cobicistat (interactions with immunosuppressants)\n\n**Key Message:**\nThere are excellent ARV options that avoid tenofovir entirely. The patient can maintain viral suppression safely with appropriate regimen selection and dose adjustments.", "metadata": {"category": "clinical", "condition": "HIV_CKD", "severity": "high", "evidence_level": "guideline", "clinical_domain": "nephrology", "source": "synthetic"}}
{"instruction": "You are a clinical decision support AI for HIV care. Provide evidence-based guidance following DHHS HIV treatment guidelines.", "input": "Patient with HIV controlled on Biktarvy for 5 years now has stage 4 CKD (eGFR 22). Nephrologist is concerned about continuing tenofovir. What are the options?", "output": "Stage 4 CKD (eGFR 22) requires careful ARV selection to avoid further renal injury while maintaining viral suppression.\n\n**Current Concern:**\n\n**Biktarvy contains TAF (tenofovir alafenamide):**\n- TAF is safer than TDF but still renally cleared\n- Not recommended below eGFR 30 in some guidelines\n- This patient is below that threshold\n- Nephrologist concern is valid\n\n**ARV Options for Advanced CKD:**\n\n**Option 1 (Preferred): Dolutegravir + Lamivudine (Dovato)**\n\n**Advantages:**\n- No tenofovir\n- DTG: Hepatic metabolism, safe in CKD\n- 3TC: Dose adjust for eGFR <50\n- Proven two-drug regimen\n\n**3TC Dosing in CKD:**\n- eGFR 30-49: 150mg daily\n- eGFR 15-29: 150mg first dose, then 100mg daily\n- eGFR <15: 150mg first dose, then 50mg daily\n\n**Important:** If HBV coinfection, cannot use Dovato (need HBV coverage)\n\n**Option 2: Dolutegravir + Rilpivirine (Juluca)**\n\n**Advantages:**\n- Two-drug regimen\n- Both hepatically metabolized\n- No dose adjustment for CKD\n\n**Disadvantages:**\n- Must take with food (400+ calories)\n- Need RPV resistance testing\n- Drug interactions (PPIs contraindicated)\n\n**Option 3: Dolutegravir monotherapy (Less preferred)**\n\n- Some data supports DTG monotherapy in suppressed patients\n- Not standard of care\n- Risk of resistance if adherence imperfect\n- Consider only if no other options\n\n**Pre-Switch Assessment:**\n\n1. **Hepatitis B status:**\n   - If HBsAg positive: Need HBV-active regimen\n   - Cannot use Dovato or Juluca alone\n   - Would need entecavir separately for HBV\n\n2. **Resistance history:**\n   - Check historical genotypes\n   - Confirm no INSTI or NNRTI resistance\n\n3. **Current viral suppression:**\n   - Confirm undetectable before switching\n\n**Recommended Approach:**\n\n```\nIf HBV negative:\n  Switch to Dovato (DTG/3TC) with 3TC dose adjusted for CKD\n  \nIf HBV positive:\n  Switch to DTG + 3TC (dose adjusted) + Entecavir\n  (Entecavir 0.5mg - also needs CKD dose adjustment)\n```\n\n**Monitoring After Switch:**\n- Viral load at 4 weeks\n- Renal function (already being monitored by nephrology)\n- HBV DNA if coinfected\n\n**Additional Considerations:**\n\n**Dialysis Planning:**\n- If progressing toward dialysis, some ARVs are dialyzable\n- DTG: Not significantly removed by dialysis\n- 3TC: Is removed - give dose after dialysis\n\n**Transplant Consideration:**\n- If transplant candidate, drug interactions will matter\n- DTG-based regimens generally preferred\n- Avoid cobicistat (interactions with immunosuppressants)\n\n**Key Message:**\nThere are excellent ARV options that avoid tenofovir entirely. The patient can maintain viral suppression safely with appropriate regimen selection and dose adjustments.", "metadata": {"category": "clinical", "condition": "HIV_CKD", "severity": "high", "evidence_level": "guideline", "clinical_domain": "nephrology", "source": "synthetic_balanced", "gender_balanced": true}}
